We conducted a survey of schistosomiasis among schoolchildren in 2 villages in Southern Sudan. In Lui (West Equatoria region), prevalence of Schistosoma mansoni infection was 51.5%; no cases of S. hematobium infection were detected. In Nyal (Upper Nile region), prevalence of S. hematobium infection was 73% and S. mansoni infection, 70%.

BACKGROUND Schistosomiasis remains one of the most common endemic parasitic diseases affecting over 230 million people worlwide. Schistosoma mansoni is the main species causing intestinal and hepatic schistosomiasis and the fresh water pulmonate snails of the genus Biomphalaria are best known for their role as intermediate hosts of the parasite. The development of new molecular monitoring assay...

Etiologic Agent Schistosomiasis is a disease caused by parasitic worm of genus Schistosoma [1]. It belongs to phylum Platyhelminthes, class Trematoda and genus Schistosoma [2]. Most human infections are caused by the three species: S. mansoni, S. haematobium, and S. japonicum [3]. There are two more species S. intercalatum and S. mekongi known to cause Schistosomiasis [3]. The most infections c...

Background Schistosomiasis remains a severe problem of public health in developing countries [1]. Several reports show that praziquantel, the drug of choice for treating schistosomiasis, can select Schistosoma mansoni strains resistant to the drug. Thus, developing new drugs against this parasitosis is a highly desirable goal [2]. In this context, enzymes involved in energetic metabolism could ...

Testicular schistosomiasis caused by Schistosoma mansoni is very rare and more so when associated with primary infertility. A 40 years old man from the Jos Plateau, North Central Nigeria presented with primary infertility after ten years of marriage. Sperm count revealed oligospermia and he also complained of inability to sustain erection. Testicular biopsy revealed several ova of Schistosoma m...

We examined the long-term efficacy of praziquantel against Schistosoma haematobium, the causative agent of urinary schistosomiasis, during a school-based treatment program in the Msambweni area of Coast Province, Kenya, where the disease is highly endemic. Our results, derived from treating 4,031 of 7,641 children from 1984 to 1993, indicate substantial year-to- year variation in drug efficacy....

A vaccine against schistosomiasis would contribute significantly to reducing the 3-70 million disability-adjusted life years lost annually to the disease. Towards this end, inoculation with the large extracellular loop (EC-2) of Schistosoma mansoni tetraspanin-2 protein (Sm-TSP-2) has proved effective in reducing worm and egg burdens in S. mansoni-infected mice. The EC-2 loop of Schistosoma jap...